Millions of U.S. Allergy Sufferers Now Have Access to Advanced Diagnostic Tests

Millions of U.S. Allergy Sufferers Now Have Access to Advanced Diagnostic Tests PlushCare’s highly trained telehealth physicians can now conveniently order Thermo Fisher Scientific blood allergy tests for patient diagnosis and treatment WALTHAM, Mass., Feb. 21, 2018 /PRNewswire/ — Millions of undiagnosed allergy sufferers, including those affected by allergy induced asthma, can now access Thermo Fisher’s advanced... Read more

Congenica Appoints New CEO to Drive Global Expansion of Clinical Genomics Business

Cambridge, United Kingdom – 25 January 2018 –Congenica, a global provider of clinical genomics interpretation software, today announced the appointment of its new Chief Executive Officer David Atkins, Ph.D. Based at the Company’s headquarters in Cambridge, UK, Dr Atkins also joins Congenica’s Board of Directors. Dr Atkins has over 25 years’ experience as a global... Read more

QIAGEN enters into agreement to acquire STAT-Dx, plans to launch a next-generation, fully integrated multiplex platform for syndromic disease testing

New system launch planned for second half of 2018 with two CE-IVD molecular diagnostics, U.S. launch planned for 2019 and broad pipeline in development Germantown, Maryland, and Hilden, Germany, January 31, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today it has entered into an agreement to acquire STAT-Dx, a privately-held company developing... Read more

Takara Bio to Establish a New Facility for the Research and Manufacturing of Regenerative Medical Products

2018/02/19 January 30, 2018 – Takara Bio’s Board of Directors resolved today to establish a new facility for the research and manufacturing of regenerative medical products in coordination with the expansion of existing research and manufacturing facilities at the company’s head office site in Kusatsu, Shiga. Total project cost is expected to be around 7.3... Read more

Illumina Awarded $26.7M in Patent Suit Against Ariosa Diagnostics, Inc.

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) announced today that a federal jury in San Francisco has ruled in its favor in a patent infringement suit filed against Ariosa Diagnostics, Inc., now owned by Roche. The jury found that both Ariosa’s previous and current version of the Harmony non-invasive prenatal test (NIPT) infringe US Patent 8,318,430... Read more

Introducing Gamithromycin on Microbroth Dilution Susceptibility Plates for Veterinary Antimicrobial Susceptibility Testing

New product expands treatment options for bovine respiratory disease (BRD) in cattle OAKWOOD VILLAGE, Ohio, Jan. 24, 2018 /PRNewswire/ — The antimicrobial gamithromycin is now available on microbroth dilution susceptibility plates, giving veterinary microbiology laboratories the means to perform susceptibility testing on organisms that cause bovine respiratory disease (BRD) in beef and non-lactating dairy cattle, and expanding... Read more

SCIEX launches high-performance mass spectrometry technology that brings ultimate sensitivity and speed to clinical diagnostics laboratories

The SCIEX Citrine™ MS/MS medical device provides clinical labs with one solution to tackle today’s difficult assays, and the versatility to address tomorrow’s precision medicine and wellness testing January 23, 2018 Framingham, MA — SCIEX Diganostics, the in vitro diagnostics division of SCIEX, a global leader in mass spectrometry in the life sciences industry, announced today the launch... Read more

Bio-Rad Gains Additional U.S. FDA Clearances for Blood Typing Products, Expanding its Offering for the Blood Testing Market

HERCULES, Calif. — January 22, 2018 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the IH-Incubator L and IH-Centrifuge L instruments to be used with the full range of Bio-Rad’s IH-System... Read more

First patient enrolled into phase I/II clinical trial of NY-ESO-1・siTCR gene therapy against synovial sarcoma in Japan

2018 2018/01/19 First patient enrolled into phase I/II clinical trial of NY-ESO-1・siTCR gene therapy against synovial sarcoma in Japan Kusatsu/Shiga, Japan — January 17, 2018 — Takara Bio Inc. (Takara Bio), today announced that the first patient with synovial sarcoma has been enrolled into NY-ESO-1・siTCR gene therapy (TBI-1301) phase I/II clinical trial in Japan on January... Read more